10x Genomics (NASDAQ:TXG) Price Target Lowered to $18.00 at Barclays

10x Genomics (NASDAQ:TXG) had its price target lowered by Barclays from $19.00 to $18.00 in a report released on Monday morning,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other equities research analysts have also recently weighed in on TXG. JPMorgan Chase & Co. dropped their price target on 10x Genomics from $20.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. UBS Group dropped their price target on 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 30th. The Goldman Sachs Group dropped their price target on 10x Genomics from $16.00 to $14.00 and set a “sell” rating on the stock in a research note on Wednesday, October 30th. Morgan Stanley dropped their price target on 10x Genomics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, February 1st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.79.

10x Genomics Price Performance

10x Genomics stock opened at $12.00 on Monday. The firm has a 50-day moving average of $14.82 and a 200-day moving average of $17.47. 10x Genomics has a one year low of $11.55 and a one year high of $51.22. The company has a market cap of $1.45 billion, a price-to-earnings ratio of -7.84 and a beta of 1.85.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. As a group, sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Institutional Trading of 10x Genomics

Large investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its holdings in shares of 10x Genomics by 451.8% during the 3rd quarter. GAMMA Investing LLC now owns 1,545 shares of the company’s stock worth $35,000 after purchasing an additional 1,265 shares in the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of 10x Genomics during the 3rd quarter worth $35,000. Blue Trust Inc. grew its holdings in shares of 10x Genomics by 136.5% during the 3rd quarter. Blue Trust Inc. now owns 1,776 shares of the company’s stock worth $40,000 after purchasing an additional 1,025 shares in the last quarter. Signaturefd LLC grew its holdings in shares of 10x Genomics by 424.6% during the 4th quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after purchasing an additional 1,452 shares in the last quarter. Finally, Sound Income Strategies LLC acquired a new stake in shares of 10x Genomics during the 3rd quarter worth $46,000. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.